Results 141 to 150 of about 10,095 (153)

Solubility measurement of a chemotherapeutic agent (Imatinib mesylate) in supercritical carbon dioxide: Assessment of new empirical model

Journal of Supercritical Fluids, 2019
Gholamhossein Sodeifian, Fariba Razmimanesh, Seyed Ali Sajadian   +2 more
exaly  

Imatinib Mesylate

2017
openaire   +1 more source

Imatinib mesylate both prevents and treats the arthritis induced by type II collagen antibody in mice

Modern Rheumatology, 2007
Kyosuke Hatsushika, Takashi Ando, Masanori Wako   +2 more
exaly  

c-KIT-expressing Ewing tumour cells are insensitive to imatinib mesylate (STI571)

Cancer Chemotherapy and Pharmacology, 2002
Marc Hotfilder, Josef Vormoor, Hotfilder Marc   +2 more
exaly  

Cost-utility analysis of imatinib mesylate for the treatment ofchronic myelogenous leukemia in the chronic phase

Clinical Therapeutics, 2004
Sue Ward, Paul A Scuffham
exaly  

Combined treatment of 3-hydroxyflavone and imatinib mesylate increases apoptotic cell death of imatinib mesylate-resistant leukemia cells

Leukemia Research, 2012
Minjung Song, Geun-Ho Kang, Eung-Ryoung Lee   +2 more
exaly  

Fatal hepatitis B virus reactivation in a chronic myeloid leukemia patient during imatinib mesylate treatment

Leukemia and Lymphoma, 2006
K Takeyama
exaly  

Antitumor activity of imatinib mesylate in neuroblastoma xenografts

Cancer Letters, 2005
Daniela Meco, Tiziana Servidei, Josef Brueggen   +2 more
exaly  

Imatinib mesylate in the treatment of chronic myeloid leukaemia

Expert Opinion on Pharmacotherapy, 2003
Brian J Druker
exaly  

Pregnancy outcomes in patients with chronic myeloid leukemia treated with imatinib mesylate: short report from a developing country

Leukemia and Lymphoma, 2014
Zeba Aziz
exaly